Evommune (EVMN) Amortizatization of Intangibles (2024 - 2026)
Evommune (EVMN) posted quarterly Amortizatization of Intangibles of $792000.0 for Q1 2026, up 86.35% year-over-year from $425000.0 in Q1 2025, and up 35.38% quarter-over-quarter from $585000.0 in Q4 2025.
Powered by 
Analysis
Evommune (EVMN) Amortizatization of Intangibles (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Amortizatization of Intangibles for 3 consecutive years, with $792000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 86.35% year-over-year to $792000.0; the TTM figure through Mar 2026 stood at $2.2 million (changed N/A YoY), while the FY2025 annual figure was $1.8 million, down 2.8% from the prior year.
- Amortizatization of Intangibles climbed to $792000.0 in Q1 2026 per EVMN's latest filing, from $585000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $792000.0 in Q1 2026 and bottomed at $425000.0 in Q1 2025.
- Historically, Amortizatization of Intangibles has averaged $562000.0 across 3 years, with a median of $515500.0 in 2024.
- Annual changes were most pronounced in 2025 — Amortizatization of Intangibles surged 31.17% — and 2026, when it soared 86.35%.
- Evommune's Amortizatization of Intangibles stood at $446000.0 in 2024, then surged by 31.17% to $585000.0 in 2025, then surged by 35.38% to $792000.0 in 2026.
- Business Quant data shows EVMN's Amortizatization of Intangibles at $792000.0 in Q1 2026, $585000.0 in Q4 2025, and $425000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Evommune | 445.19 Mn | 244.40 Mn | - | 756,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 756,000.00 |
| Mar 31, 2026 | 792,000.00 |
| Dec 31, 2025 | 585,000.00 |
| Sep 30, 2025 | 511,000.00 |
| Jun 30, 2025 | 248,000.00 |
| Mar 31, 2025 | 425,000.00 |
| Dec 31, 2024 | 446,000.00 |